Arthneeti
All Q2 FY27 results →
RB

Rossari Biotech

Q2 FY27Chemicals & Petrochemicals

Rossari Biotech Q2 FY27 investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹455
Market cap₹2.5K Cr
P/E16.5
Updated18 Oct 2026
Read3 min read

Based on Rossari Biotech's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Revenue from operations for the quarter ended 30th September 2026 (Standalone): Rs. EBITDA for the quarter ended 30th September 2026: Rs.

From Rossari Biotech's Q2 FY27 earnings-call transcript · updated 18 Oct 2026.

Revenue & Sales Performance

  • Revenue from operations for the quarter ended 30th September 2026 (Standalone): Rs. 4,952.76 million.
  • Revenue from operations for the quarter ended 30th September 2025 (Standalone): Rs. 4,195.12 million.
  • Year-on-year revenue growth (Standalone) for the quarter: Rs. 4,952.76 million vs Rs. 4,195.12 million, an increase of approximately 18%.
  • Revenue from operations for the quarter ended 30th September 2026 (Consolidated): Rs. 6,975.60 million.
  • Revenue from operations for the quarter ended 30th September 2025 (Consolidated): Rs. 5,861.07 million.

2 more points from Rossari Biotech's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Rossari Biotech said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The Board approved leasing of land by Rossari International Limited (wholly owned subsidiary) for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA).
  • Detailed project plan, including nature and overall investment, is pending finalization and will be placed before the Board for approval later.
  • No specific capex amounts, capacity expansion figures, or timelines are disclosed in the current presentation.
  • Further disclosures on the project will be made as required when material developments occur.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any figures or details related to order book, order inflow, or pending orders. The provided pages include financial results, statements of cash flow, auditor's reports, and disclosures on leasing land for manufacturing facilities, but no specific mention or data concerning order book status is present.

Rossari Biotech — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Rossari Biotech's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • GOCL Corpn. (Q2 FY27)

    Year-on-year (YoY) increase in revenue from operations: Approximately 85% increase (41,063 vs. Key results statement takeaways from GOCL Corpn.'s Q2 FY27 result

  • AksharChem (I) (Q2 FY27)

    Year-on-year revenue growth for the quarter is approximately 79.7% [(16,048.24 . Key results statement takeaways from AksharChem (I)'s Q2 FY27 results statement

  • Bhansali Engineering Polymers Ltd (Q2 FY27)

    Revenue from operations (net) for the quarter ended 30/09/2026 is ₹40,336.95 lakhs, compared to ₹32,509.76 lakhs for the quarter ended 30/09/2025, reflecting a…

  • Tatva Chintan (Q2 FY27)

    Q2 FY27 revenue from operations: ₹2,173 Mn, up 76% YoY from ₹1,235 Mn in Q2 FY26 (Page 11). Key investor presentation takeaways from Tatva Chintan's Q2 FY27 inv

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Rossari Biotech and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Rossari Biotech Q2 FY27 results?

Revenue from operations for the quarter ended 30th September 2026 (Standalone): Rs. EBITDA for the quarter ended 30th September 2026: Rs.

What is Rossari Biotech share price analysis?

Rossari Biotech currently shows a neutral. The stock trades at a P/E of 16.5 with a market cap of ₹2,518 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech planning capital expenditure?

The Board approved leasing of land by Rossari International Limited (wholly owned subsidiary) for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA).

Keep Rossari Biotech on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.